- In individuals with ongoing viraemia and with
few options to construct a fully suppressive regimen, referral for specialist
advice and/or discussion in a multidisciplinary team ‘virtual’ clinic is
- In those with significant resistance, include
at least two and preferably three fully active agents with at least one
active PI/r (preferably DRV/r) and one agent with a novel mechanism of action
(preferably intergrase inhibitor, or CCR5 antagonist or fusion inhibitor).
- Treatment interruption is not recommended.